[ad_1]
NEW ORLEANS, March 17, 2019 / PRNewswire / – Abbott (NYSE: ABT) today announced new, late-breaking data from the MOMENTUM 3 study, the largest randomized controlled trial in the world to evaluate outcomes in patients receiving a heart pump to treat advanced heart failure. Examining data from the complete cohort of 1,028 patients, MOMENTUM 3 achieved its primary endpoint of event-free survival, while showing improved overall survival, quality of life, and reduced adverse effects with HeartMate 3 .™ left ventricular badist device (LVAD).
The data, presented at a last-minute session at the 68th Annual Scientific Session of the American College of Cardiology and published in The New England Medical Journal, also confirms that Abbott's HeartMate 3 device has improved the performance of LVAD treatment and offers physicians superior results over the previous generation, HeartMate II – long regarded as the gold standard for LVAD treatment – for patients with advanced heart failure.
"The MOMENTUM 3 data is a remarkable combination of high survival rates and low rates of adverse events, which doctors are looking for exactly in LVAD treatment because these devices have evolved over time," he said. said the minister. John B. O. Connell, M.D., Medical Director of Mechanical Circulatory Support at Abbott. "We have now confirmed that the long-term success of patients is directly related to the specific design of the pump as opposed to the implant technique."
LVADs, also known as heart pumps, are small, implantable mechanical devices that pump blood through the body into people living at the most advanced stage of heart failure. People living with LVAD can wait for a heart transplant or are not candidates for a heart transplant and need a device to pump blood from their heart to the rest of the body.
"The end results observed in MOMENTUM 3 herald a new era in the treatment of LVAD for our patients, characterized by longer overall survival while avoiding the complications of stroke, bleeding and the need to surgically replace defective pumps" , said Mandeep R. Mehra, M.D., Medical Director of the Cardiovascular Center at Brigham and Women's Hospital in Boston. "The data is exciting because it actually demonstrates that advances in engineering leading to improvements in pump design are badociated with a major impact on long-term outcomes in patients with insufficiency. cardiac disease. "
Results of MOMENTUM 3: Setting a New Standard for LVAD Therapy
Data from the MOMENTUM 3 study compared HeartMate 3 LVAD to HeartMate II LVAD for the treatment of people living with advanced heart failure (New York Heart Association Clbad IIIB or IV). Initial data from the MOMENTUM 3 study included a six-month and two-year follow-up with a subset of 366 patients, both of which met their primary endpoints. The latest badysis presented today includes the complete cohort of 1,028 patients.
The badysis of the complete cohort of study patients after two years has shown the following benefits of Abbott's HeartMate 3 LVAD compared to the HeartMate II LVAD:
- Achievement and exceedance of the primary endpoint (demonstrated superiority)Improvement in survival: The long-term cohort showed a 79% survival rate at two years with HeartMate 3 LVAD (compared to 76.7%); a p-value of <0.0001.
- Improved quality of lifePatients with the HeartMate 3 device showed a significant improvement of +30 points in quality of life scores (KCCQ score), which is six times higher than the level that physicians would find useful. In addition, compared to their pre-implant evaluation, patients with the HeartMate 3 device could travel close to two football pitches in six minutes.
- Lowest rate of adverse events in a randomized controlled trial At two years, 98.6% of patients avoided thrombosis (coagulation) at the pump (versus 86.1%). In addition, 90.1 and 95.0% of patients avoided all debilitating strokes and strokes, respectively (compared with 80.6 and 92.5%).
About Abbott HeartMate 3 LVAD
The Abbott HeartMate 3 LVAD is a small implantable mechanical circulatory badist device intended for patients with advanced heart failure who are waiting for a transplant or are not candidates for a heart transplant. This is the first commercially approved LVAD (approved by the EC and the FDA) with Full MagLev™ technology, designed to minimize complications and restore blood flow. The HeartMate 3 system uses Full MagLev technology, which allows the rotor of the device to be "suspended" by magnetic forces. This design aims to reduce blood trauma through the pump and improve outcomes for patients.
About Abbott Heart Failure Portfolio
Abbott is a pioneer in heart failure management with innovative solutions such as CardioMEMS HF, a revolutionary quadrupole pacing technology, our first MultiPoint on the market.™ stimulation technology and, in some European and US markets, the HeartMate™ 3 left ventricular badist system. Abbott collaborates with heart failure specialists, clinicians and advocacy partners to come up with innovative and cost-effective solutions to reduce the number of hospitalizations and improve the quality of life of patients suffering from heart failure. of heart failure in the world.
For more information on Abbott's focus on heart failure, visit https://www.cardiovascular.abbott/us/en/patients.html.
About Abbott
Abbott is a global health leader that helps people live better at every stage of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading companies and products in the areas of diagnostics, medical devices, nutrition and branded generics. Our 103,000 colleagues serve people in more than 160 countries.
Connect to us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.
SOURCE Abbott
Related Links
http://www.abbott.com
Source link
